175 related articles for article (PubMed ID: 10408377)
1. Decay acceleration of the complement alternative pathway C3 convertase.
Hourcade DE; Mitchell LM; Medof ME
Immunopharmacology; 1999 May; 42(1-3):167-73. PubMed ID: 10408377
[TBL] [Abstract][Full Text] [Related]
2. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
3. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.
Hourcade DE; Mitchell L; Kuttner-Kondo LA; Atkinson JP; Medof ME
J Biol Chem; 2002 Jan; 277(2):1107-12. PubMed ID: 11694537
[TBL] [Abstract][Full Text] [Related]
4. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement.
Pangburn MK; Pangburn KL; Koistinen V; Meri S; Sharma AK
J Immunol; 2000 May; 164(9):4742-51. PubMed ID: 10779780
[TBL] [Abstract][Full Text] [Related]
6. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.
Pangburn MK
Immunology; 1990 Dec; 71(4):598-600. PubMed ID: 1703989
[TBL] [Abstract][Full Text] [Related]
7. Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.
Kwon YC; Kim H; Meyer K; Di Bisceglie AM; Ray R
J Immunol; 2016 Aug; 197(4):1127-36. PubMed ID: 27357152
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the active sites in decay-accelerating factor.
Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
[TBL] [Abstract][Full Text] [Related]
9. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
[TBL] [Abstract][Full Text] [Related]
10. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
[TBL] [Abstract][Full Text] [Related]
11. Structure/function studies of human decay-accelerating factor.
Brodbeck WG; Kuttner-Kondo L; Mold C; Medof ME
Immunology; 2000 Sep; 101(1):104-11. PubMed ID: 11012760
[TBL] [Abstract][Full Text] [Related]
12. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
Hebecker M; Józsi M
J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
[TBL] [Abstract][Full Text] [Related]
13. Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases.
Krych-Goldberg M; Hauhart RE; Subramanian VB; Yurcisin BM; Crimmins DL; Hourcade DE; Atkinson JP
J Biol Chem; 1999 Oct; 274(44):31160-8. PubMed ID: 10531307
[TBL] [Abstract][Full Text] [Related]
14. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
[TBL] [Abstract][Full Text] [Related]
15. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
16. A C3 convertase assay for nephritic factor functional activity.
Jelezarova E; Schlumberger M; Sadallah S; Späth PJ; Schifferli JA; Lutz HU
J Immunol Methods; 2001 May; 251(1-2):45-52. PubMed ID: 11292480
[TBL] [Abstract][Full Text] [Related]
17. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
18. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
19. A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases.
Kuttner-Kondo LA; Dybvig MP; Mitchell LM; Muqim N; Atkinson JP; Medof ME; Hourcade DE
J Biol Chem; 2003 Dec; 278(52):52386-91. PubMed ID: 14561755
[TBL] [Abstract][Full Text] [Related]
20. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55).
Harris CL; Abbott RJ; Smith RA; Morgan BP; Lea SM
J Biol Chem; 2005 Jan; 280(4):2569-78. PubMed ID: 15536079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
